AJO LP’s Harvard Bioscience HBIO Stock Holding History

AJO LP’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,447	Closed	-$284K	–	431
2020 Q3	$284K	Buy	9,447 +7,220	+324%	+$243K	﹤0.01%	589
2020 Q2	$69K	Buy	+2,227	New	+$60K	﹤0.01%	644

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AJO LP's HBIO Position: Q4 2020 in Review

AJO LP sold out of Harvard Bioscience (HBIO) in Q4 2020, closing a stake of 9,447 shares — an estimated $284K sold.

AJO LP first reported a position in HBIO in Q2 2020 and held it in 2 quarters. The position peaked at $284K in Q3 2020. 81 funds tracked by Wall St. Rank hold HBIO as of Q4 2020.

AJO LP reported no remaining Harvard Bioscience position as of Q4 2020 after selling out during the quarter.
AJO LP sold 9,447 Harvard Bioscience shares in Q4 2020, an estimated $284K.
AJO LP first reported a position in Harvard Bioscience in Q2 2020 and held it in 2 quarters.
AJO LP's Harvard Bioscience position peaked at $284K in Q3 2020.
81 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2020.

Based on AJO LP's 13F filing for Q4 2020, filed 5 Feb 2021.